Ethosuximide modifies network excitability in the rat entorhinal cortex via an increase in GABA release

Stuart D. Greenhill, Peter Massey, Nicola Morgan, Gavin Woodhall, Roland S.G. Jones

Research output: Contribution to journalArticle

Abstract

Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and, thus, generation of spike-wave activity in thalamocortical pathways. However, there is now good evidence that generalized absence seizures may be initiated at a cortical focus and that ethosuximide may target this focus. In the present study we have looked at the effect ethosuximide on glutamate and GABA release at synapses in the rat entorhinal cortex in vitro, using two experimental approaches. Whole-cell patch-clamp studies revealed an increase in spontaneous GABA release by ethosuximide concurrent with no change in glutamate release. This was reflected in studies that estimated global background inhibition and excitation from intracellularly recorded membrane potential fluctuations, where there was a substantial rise in the ratio of network inhibition to excitation, and a concurrent decrease in excitability of neurones embedded in this network. These studies suggest that, in addition to well-characterised effects on ion channels, ethosuximide may directly elevate synaptic inhibition in the cortex and that this could contribute to its anti-absence effects. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.
Original languageEnglish
Pages (from-to)807-814
Number of pages8
JournalNeuropharmacology
Volume62
Issue number2
Early online date16 Sep 2011
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Ethosuximide
Entorhinal Cortex
gamma-Aminobutyric Acid
Absence Epilepsy
Glutamic Acid
Seizures
Post-Traumatic Stress Disorders
Ion Channels
Membrane Potentials
Synapses
Neurons
Pharmaceutical Preparations
Inhibition (Psychology)

Bibliographical note

© 2011, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords

  • entorhinal cortex
  • anticonvulsants
  • presynaptic terminals
  • ethosuximide
  • glutamate release
  • GABA release
  • excitability

Cite this

@article{e113bab1537a4cfcbe383649d9baeb96,
title = "Ethosuximide modifies network excitability in the rat entorhinal cortex via an increase in GABA release",
abstract = "Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and, thus, generation of spike-wave activity in thalamocortical pathways. However, there is now good evidence that generalized absence seizures may be initiated at a cortical focus and that ethosuximide may target this focus. In the present study we have looked at the effect ethosuximide on glutamate and GABA release at synapses in the rat entorhinal cortex in vitro, using two experimental approaches. Whole-cell patch-clamp studies revealed an increase in spontaneous GABA release by ethosuximide concurrent with no change in glutamate release. This was reflected in studies that estimated global background inhibition and excitation from intracellularly recorded membrane potential fluctuations, where there was a substantial rise in the ratio of network inhibition to excitation, and a concurrent decrease in excitability of neurones embedded in this network. These studies suggest that, in addition to well-characterised effects on ion channels, ethosuximide may directly elevate synaptic inhibition in the cortex and that this could contribute to its anti-absence effects. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.",
keywords = "entorhinal cortex, anticonvulsants, presynaptic terminals, ethosuximide, glutamate release, GABA release, excitability",
author = "Greenhill, {Stuart D.} and Peter Massey and Nicola Morgan and Gavin Woodhall and Jones, {Roland S.G.}",
note = "{\circledC} 2011, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/",
year = "2012",
month = "2",
doi = "10.1016/j.neuropharm.2011.09.006",
language = "English",
volume = "62",
pages = "807--814",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier",
number = "2",

}

Ethosuximide modifies network excitability in the rat entorhinal cortex via an increase in GABA release. / Greenhill, Stuart D.; Massey, Peter; Morgan, Nicola; Woodhall, Gavin; Jones, Roland S.G.

In: Neuropharmacology, Vol. 62, No. 2, 02.2012, p. 807-814.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ethosuximide modifies network excitability in the rat entorhinal cortex via an increase in GABA release

AU - Greenhill, Stuart D.

AU - Massey, Peter

AU - Morgan, Nicola

AU - Woodhall, Gavin

AU - Jones, Roland S.G.

N1 - © 2011, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

PY - 2012/2

Y1 - 2012/2

N2 - Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and, thus, generation of spike-wave activity in thalamocortical pathways. However, there is now good evidence that generalized absence seizures may be initiated at a cortical focus and that ethosuximide may target this focus. In the present study we have looked at the effect ethosuximide on glutamate and GABA release at synapses in the rat entorhinal cortex in vitro, using two experimental approaches. Whole-cell patch-clamp studies revealed an increase in spontaneous GABA release by ethosuximide concurrent with no change in glutamate release. This was reflected in studies that estimated global background inhibition and excitation from intracellularly recorded membrane potential fluctuations, where there was a substantial rise in the ratio of network inhibition to excitation, and a concurrent decrease in excitability of neurones embedded in this network. These studies suggest that, in addition to well-characterised effects on ion channels, ethosuximide may directly elevate synaptic inhibition in the cortex and that this could contribute to its anti-absence effects. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.

AB - Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and, thus, generation of spike-wave activity in thalamocortical pathways. However, there is now good evidence that generalized absence seizures may be initiated at a cortical focus and that ethosuximide may target this focus. In the present study we have looked at the effect ethosuximide on glutamate and GABA release at synapses in the rat entorhinal cortex in vitro, using two experimental approaches. Whole-cell patch-clamp studies revealed an increase in spontaneous GABA release by ethosuximide concurrent with no change in glutamate release. This was reflected in studies that estimated global background inhibition and excitation from intracellularly recorded membrane potential fluctuations, where there was a substantial rise in the ratio of network inhibition to excitation, and a concurrent decrease in excitability of neurones embedded in this network. These studies suggest that, in addition to well-characterised effects on ion channels, ethosuximide may directly elevate synaptic inhibition in the cortex and that this could contribute to its anti-absence effects. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.

KW - entorhinal cortex

KW - anticonvulsants

KW - presynaptic terminals

KW - ethosuximide

KW - glutamate release

KW - GABA release

KW - excitability

UR - http://www.scopus.com/inward/record.url?scp=84855916993&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2011.09.006

DO - 10.1016/j.neuropharm.2011.09.006

M3 - Article

VL - 62

SP - 807

EP - 814

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 2

ER -